Skip to main content

Table 1 Main minimum global policy options considered for the economic analysis. We assume that countries using IPV-only at T0 will continue to do so indefinitely regardless of the policy choice.

From: An economic analysis of poliovirus risk management policy options for 2013–2052

Policy abbreviation Description Characterization in countries using OPV-only at T0 (LOW, LMI, or UMI) Characterization in countries using IPV/OPV at T0 (UMI or HIGH)
RC with SIAs Continued status quo Continue tOPV-only indefinitely for RI supplemented with bOPV and tOPV SIAs Continue IPV/OPV indefinitely supplemented with bOPV and tOPV SIAs
RC no SIAs Continued status quo, but with no SIAs from 1/1/2019 Continue tOPV-only indefinitely for RI supplemented with bOPV and tOPV SIAs until 1/1/2019 Continue IPV/OPV indefinitely supplemented with bOPV and tOPV SIAs until 1/1/2019
IPV5 Current plan [19] with IPV everywhere for 5 years after all-OPV cessation • Add IPV doses to RI schedule on 1/1/2015a • Replace all tOPV with bOPV on 4/1/2016
• Replace all tOPV with bOPV on 4/1/2016 • OPV13 cessation on 4/1/2019, switch RI to IPV-only indefinitely
• OPV13 cessation on 4/1/2019b
• IPV cessation on 4/1/2024 in LOW and LMI countries
IPV10 Current plan [19] with IPV everywhere for 10 years after all-OPV cessation • Same as above but with IPV cessation of 4/1/2029 in LOW and LMI countries • Same as above
IPV through Tend Current plan [19] with IPV everywhere until at least T end • Same as above but without IPV cessation anywhere • Same as above
No IPV Current plan [19] but without global IPV use after OPV cessation of any type • Replace all tOPV with bOPV on 4/1/2016 • Replace all tOPV with bOPV on 4/1/2016
• OPV13 cessation on 4/1/2019 • OPV13 cessation on 4/1/2019, switch RI to IPV-only indefinitely
  1. Abbreviations: bOPV, bivalent OPV (serotypes 1 and 3); HIGH, high-income; IPV, inactivated poliovirus vaccine; LMI, lower middle-income; LOW, low-income; OPV, oral poliovirus vaccine; OPV13 cessation, globally-coordinated cessation of OPV containing serotypes 1 and 3; RC, reference case; RI, routine immunization; SIA, supplemental immunization activity; T0, beginning of analytical time horizon (i.e., January 1, 2013); Tend, end of analytical time horizon (i.e., December 31, 2052); tOPV, trivalent OPV; UMI, upper middle-income
  2. a Assumes a single IPV dose administered synchronously with OPV to any child that receives at least one non-birth OPV RI dose in LOW and LMI countries, but a sequential IPV/IPV/OPV/OPV schedule in UMI countries
  3. b Assumes LOW and LMI countries continue with a single-dose IPV schedule while UMI countries switch to a 3-dose IPV-only RI schedule indefinitely